Answers are grounded in this paper and cite their sources.
Signal sequence receptor subunit 4 (SSR4), or TRAPδ, is an endoplasmic-reticulum component of the translocon-associated protein complex and participates in selective protein biogenesis at the interface of translocation and glycoprotein processing. Its biological effects, however, appear to depend strongly on cellular context. This Review organizes current evidence according to the cell type in which SSR4 is measured, the phenotype that depends on it, and the protein-processing event proposed to connect the two. In cancer-cell models, SSR4 perturbation affects cellular fitness, but the proposed oxidative-phosphorylation mechanism in gastric cancer has not been tested by direct respiratory-flux measurements or downstream-effector rescue. Upstream studies also indicate that SSR4 abundance can be regulated post-transcriptionally, although the phenotypic consequences of this regulation remain unresolved. In B cells, conditional Ssr4 deletion impairs peripheral B-cell maintenance and is accompanied by BAFFR-associated glycosylation changes, attenuated non-canonical NF-κB signaling, and altered lymphoid-cell composition and organization. These findings do not establish BAFFR as the mediator of the tumor phenotype, tertiary lymphoid structures as the cause of altered tumor burden, or SSR4 as a predictor of checkpoint-inhibitor benefit. β-cell and congenital glycosylation studies further demonstrate physiological dependence on SSR4, while its X-linked inheritance raises unresolved questions about functional dosage. Overall, current evidence supports SSR4 as a context-dependent component of ER protein biogenesis rather than a uniformly oncogenic or protective factor. Translationally, the immediate priority is to establish on-target SSR4 dependence and phenotype-mediating clients, followed by assessment of compartment-specific therapeutic windows and pharmacological target engagement; compartment-resolved clinical biomarker validation represents a parallel evidence track.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: